211 related articles for article (PubMed ID: 1739355)
21. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.
Cometta A; Calandra T; Gaya H; Zinner SH; de Bock R; Del Favero A; Bucaneve G; Crokaert F; Kern WV; Klastersky J; Langenaeken I; Micozzi A; Padmos A; Paesmans M; Viscoli C; Glauser MP
Antimicrob Agents Chemother; 1996 May; 40(5):1108-15. PubMed ID: 8723449
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients.
Liu CY; Wang FD
Chemotherapy; 1989; 35 Suppl 2():16-22. PubMed ID: 2692982
[TBL] [Abstract][Full Text] [Related]
23. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
Charnas R; Lüthi AR; Ruch W
Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients.
Miller JA; Butler T; Beveridge RA; Kales AN; Binder RA; Smith LJ; Ueno WM; Milkovich G; Goldwater S; Marion A
Clin Ther; 1993; 15(3):486-99. PubMed ID: 8364941
[TBL] [Abstract][Full Text] [Related]
25. Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients.
Nucci M; Biasoli I; Braggio S; Portugal R; Schaffel R; Maiolino A; Loureiro MM; Spector N; Pulcheri W
Oncol Rep; 1998; 5(5):1205-9. PubMed ID: 9683836
[TBL] [Abstract][Full Text] [Related]
26. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.
; Calandra T; Klastersky J; Gaya H; Glauser MP; Meunier F; Zinner SH
N Engl J Med; 1987 Dec; 317(27):1692-8. PubMed ID: 2892130
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
[TBL] [Abstract][Full Text] [Related]
28. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group.
De Pauw BE; Deresinski SC; Feld R; Lane-Allman EF; Donnelly JP
Ann Intern Med; 1994 May; 120(10):834-44. PubMed ID: 8154643
[TBL] [Abstract][Full Text] [Related]
29. Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients.
Verhagen CS; de Pauw B; de Witte T; Janssen J; Williams K; de Mulder P; Bothof T
Antimicrob Agents Chemother; 1987 Feb; 31(2):191-6. PubMed ID: 3551829
[TBL] [Abstract][Full Text] [Related]
30. Aztreonam plus vancomycin (plus amikacin) vs. moxalactam plus ticarcillin for the empiric treatment of febrile episodes in neutropenic cancer patients.
Jones P; Rolston K; Fainstein V; Elting L; Bodey GP
Rev Infect Dis; 1985; 7 Suppl 4():S741-6. PubMed ID: 3909332
[TBL] [Abstract][Full Text] [Related]
31. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
Menichetti F; Martino P; Bucaneve G; Gentile G; D'Antonio D; Liso V; Ricci P; Nosari AM; Buelli M; Carotenuto M
Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
[TBL] [Abstract][Full Text] [Related]
32. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study.
de la Cámara R; Figuera A; Sureda A; Hermida G; Verge G; Olalla I; Fernández Rañada JM; Domingo Albos A
Haematologica; 1997; 82(6):668-75. PubMed ID: 9580087
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial comparing netilmicin plus imipenem-cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients.
Laszlo D; Bacci S; Bosi A; Fanci R; Guidi S; Saccardi R; Vannucchi AM; Rossi Ferrini P
J Chemother; 1997 Apr; 9(2):95-101. PubMed ID: 9176746
[TBL] [Abstract][Full Text] [Related]
34. Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer.
Wade JC; Standiford HC; Drusano GL; Johnson DE; Moody MR; Bustamante CI; Joshi JH; deJongh C; Schimpff SC
Am J Med; 1985 Jun; 78(6A):62-72. PubMed ID: 3859217
[TBL] [Abstract][Full Text] [Related]
35. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
[TBL] [Abstract][Full Text] [Related]
36. Randomized clinical trial comparing ceftriaxone/amikacin versus ceftazidime/amikacin as initial therapy of febrile episodes in neutropenic patients.
Yataganas X; Rombos Y; Vayopoulos G; Meletis J; Avlami A
Chemotherapy; 1991; 37(5):376-81. PubMed ID: 1804599
[TBL] [Abstract][Full Text] [Related]
37. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
[TBL] [Abstract][Full Text] [Related]
38. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem.
Freifeld AG; Walsh T; Marshall D; Gress J; Steinberg SM; Hathorn J; Rubin M; Jarosinski P; Gill V; Young RC
J Clin Oncol; 1995 Jan; 13(1):165-76. PubMed ID: 7799016
[TBL] [Abstract][Full Text] [Related]
39. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey.
Akova M; Akan H; Korten V; Biberoğlu K; Hayran M; Unal S; Kars A; Kansu E
Int J Antimicrob Agents; 1999 Sep; 13(1):15-9. PubMed ID: 10563400
[TBL] [Abstract][Full Text] [Related]
40. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone.
Winston DJ; Ho WG; Bruckner DA; Champlin RE
Ann Intern Med; 1991 Dec; 115(11):849-59. PubMed ID: 1952471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
